title: Effect of long-chain polyunsaturated fatty acid supplementation of preterm infants on disease risk and neurodevelopment: a systematic review of randomized controlled trials.
abstract: BACKGROUND
  Supplementation of preterm formulas with long-chain polyunsaturated fatty acids (LCPUFAs) is based on their effectiveness to increase blood status and improve visual outcomes. Dispute remains over their efficacy on global development.
  
  
  OBJECTIVE
  The objective was to compare the effects of LCPUFA-supplemented with those of control formulas on neurodevelopment and diseases associated with prematurity.
  
  
  METHODS
  We systematically reviewed randomized controlled trials involving preterm infants that tested LCPUFA-supplemented formulas. The weighted mean differences (WMDs) in neurodevelopmental scores and relative risk (RR) of disease were calculated to compare infants fed LCPUFA-supplemented formula with those fed control formula.
  
  
  RESULTS
  No clear differences in Bayley Scales of Infant Development (BSID) scores were observed between groups. Mental development of LCPUFA-supplemented infants was 3.4 points higher than that of control infants with BSID version II (WMD: 3.44; 95% CI: 0.56, 6.31; P = 0.02; n = 879), although it was driven by 2 trials with large effect sizes and wide CIs. Psychomotor development was lower in supplemented infants tested with BSID version I (WMD: -7.99; 95% CI: -14.00, -1.99; P = 0.009; n = 87); however, it was limited by small sample sizes. No differences in the RR of sepsis (1.08; 95% CI: 0.79, 1.46; P = 0.63; n = 1333) or in the RR of necrotizing enterocolitis (1.13; 95% CI: 0.62, 2.04; P = 0.69; n = 1333) were found. Similarly, the risks of retinopathy of prematurity, intraventricular hemorrhage, and bronchopulmonary dysplasia were not different between groups, but data were limited by small sample sizes and trials with an increased risk of bias.
  
  
  CONCLUSIONS
  LCPUFA-supplemented formula does not alter the risk of NEC or sepsis. Further work is needed to determine the extent of benefit of LCPUFA-supplemented formula on the mental development of preterm infants.
authors.affiliation: Child Health Research Institute, Child, Youth and Women's Health Service, North Adelaide, Australia.
authors.forename: Lisa G
authors.initials: LG
authors.lastname: Smithers
authors.forename: Robert A
authors.initials: RA
authors.lastname: Gibson
authors.forename: Andrew
authors.initials: A
authors.lastname: McPhee
authors.forename: Maria
authors.initials: M
authors.lastname: Makrides
mesh_terms: D002657:Child Development / Q000187:drug effects* / Q000502:physiology; D003071:Cognition / Q000187:drug effects; D019587:Dietary Supplements; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007223:Infant; D041943:Infant Formula / Q000737:chemistry*; D007227:Infant Nutritional Physiological Phenomena / Q000502:physiology*; D007231:Infant, Newborn; D007234:Infant, Premature / Q000254:growth & development*; D008297:Male; D008603:Mental Health; D009752:Nutritional Status; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D018805:Sepsis / Q000453:epidemiology; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D005231:Fatty Acids, Unsaturated